Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RARB | P10826 | 4/20 | 0.61 |
| ▸ | NR5A1 | Q13285 | 1/20 | 0.59 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.58 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.58 |
| ▸ | LTA4H | P09960 | 3/20 | 0.53 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.53 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.53 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.53 |
| ▸ | TP53 | P04637 | 1/20 | 0.53 |
| ▸ | TSHR | P16473 | 1/20 | 0.53 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 1/20 | 0.52 |
| ▸ | PLA2G4B | P0C869 | 1/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | HPGD | P15428 | 2/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7697448 | 1.00 | RARB (0.61) | RARBNR5A1CYP3A4CYP2D6LTA4H | |
| SCHEMBL12972983 | 1.00 | RARB (0.61) | RARBNR5A1CYP3A4CYP2D6LTA4H | |
| SCHEMBL2356412 | 1.00 | RARB (0.61) | RARBNR5A1CYP3A4CYP2D6LTA4H | |
| SCHEMBL1792760 | 1.00 | RARB (0.61) | RARBNR5A1CYP3A4CYP2D6LTA4H | |
| SCHEMBL4867079 | 1.00 | RARB (0.61) | RARBNR5A1CYP3A4CYP2D6LTA4H | |
| SCHEMBL2357155 | 0.98 | CYP2D6 (0.59) | RARBNR5A1CYP3A4CYP2D6LTA4H | |
| SCHEMBL7330936 | 0.94 | CYP2D6 (0.63) | RARBCYP3A4CYP2D6LTA4HCYP19A1 | |
| SCHEMBL1102341 | 0.94 | NR5A1 (0.66) | RARBNR5A1LTA4HTP53TSHR | |
| SCHEMBL8215140 | 0.94 | NR5A1 (0.66) | RARBNR5A1LTA4HTP53TSHR | |
| SCHEMBL6740617 | 0.94 | NR5A1 (0.66) | RARBNR5A1LTA4HTP53TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8921309-B2 | Lipopeptide compounds and their use | UNIQUEST PTY LIMITED (AU) | 2014-12-30 | — | — | US | disclosed |
| US-8921309-B2 | Lipopeptide compounds and their use | UNIQUEST PTY LIMITED (AU) | 2014-12-30 | — | — | US | disclosed |
| US-8921309-B2 | Lipopeptide compounds and their use | UNIQUEST PTY LIMITED (AU) | 2014-12-30 | — | — | US | disclosed |
| EP-2350119-B1 | LIPOPEPTIDE COMPOUNDS AND THEIR USE | UNIQUEST PTY LTD (AU) | 2014-10-29 | — | — | EP | disclosed |
| EP-2350119-B1 | LIPOPEPTIDE COMPOUNDS AND THEIR USE | UNIQUEST PTY LTD (AU) | 2014-10-29 | — | — | EP | disclosed |
| US-20110224129-A1 | Lipopeptide Compounds and Their Use | MERLION PHARMACEUTICALS PTE LTD (SG) | 2011-09-15 | — | — | US | disclosed |
| US-20110224129-A1 | Lipopeptide Compounds and Their Use | MERLION PHARMACEUTICALS PTE LTD (SG) | 2011-09-15 | — | — | US | disclosed |
| US-20110224129-A1 | Lipopeptide Compounds and Their Use | MERLION PHARMACEUTICALS PTE LTD (SG) | 2011-09-15 | — | — | US | disclosed |
| EP-2350119-A1 | LIPOPEPTIDE COMPOUNDS AND THEIR USE | Merlion Pharmaceuticals Pte Ltd. (SG) | 2011-08-03 | — | — | EP | disclosed |
| WO-2010062264-A1 | LIPOPEPTIDE COMPOUNDS AND THEIR USE | MERLION PHARMACEUTICALS PTE LTD (SG) | 2010-06-03 | — | — | WO | disclosed |
| EP-0409634-A2 | Liquid crystal compounds and optically active compounds | SANYO CHEMICAL INDUSTRIES LTD. (JP) | 1991-01-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110224129-A1 | Lipopeptide Compounds and Their Use | VIP, LTA, CLPTM1 | RARB 2792/4885NR5A1 3242/4885CYP3A4 4760/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.